ArticleAntibiotics (Basel, Switzerland)2020
Antimicrobial Resistance and Genomic Characterization of OXA-48- and CTX-M-15-Co-Producing Hypervirulent
Article in Antibiotics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 36 citations in OpenAlex.
- Article
- Study Protocol for Genomic Epidemiology Investigation of Intensive Care Unit Patient Colonization by Antimicrobial-Resistant ESKAPE Pathogens.Methods and protocols · 2025Article
- Review
- Carbapenemase-Producing Enterobacterales from Patients Arriving from Ukraine in Poland, March 2022-February 2023.Infectious diseases and therapy · 2025Article
- Virulence Factors inIndian journal of microbiology · 2024Review
- Whole-Genome Sequencing Revealed the Fusion Plasmids Capable of Transmission and Acquisition of Both Antimicrobial Resistance and Hypervirulence Determinants in Multidrug-ResistantMicroorganisms · 2023Article
- Genomic analysis of the international high-risk clonal lineage Klebsiella pneumoniae sequence type 395.Genome medicine · 2023Article
- High-Molecular-Weight Plasmids Carrying Carbapenemase GenesMicroorganisms · 2023Article
- Plasmid Composition, Antimicrobial Resistance and Virulence Genes Profiles of Ciprofloxacin- and Third-Generation Cephalosporin-Resistant FoodborneMicroorganisms · 2023Article
- Virulence factors in carbapenem-resistant hypervirulentFrontiers in microbiology · 2023Review
- Molecular Epidemiology ofMicroorganisms · 2022Article
- Long-Read Whole Genome Sequencing Elucidates the Mechanisms of Amikacin Resistance in Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2022Article
- The Characteristics of Multilocus Sequence Typing, Virulence Genes and Drug Resistance ofAnimals : an open access journal from MDPI · 2022Article
- Whole-Genome Analysis ofFoods (Basel, Switzerland) · 2022Article
- OXA-48-Like β-Lactamases: Global Epidemiology, Treatment Options, and Development Pipeline.Antimicrobial agents and chemotherapy · 2022Review
- In Vitro and In Vivo Assessments of Two Newly Isolated Bacteriophages against an ST13 Urinary Tract InfectionViruses · 2022Article
- Massive Spread of OXA-48 Carbapenemase-Producing Enterobacteriaceae in the Environment of a Swiss Companion Animal Clinic.Antibiotics (Basel, Switzerland) · 2022Article
- Epidemiological characteristics and molecular evolution mechanisms of carbapenem-resistant hypervirulentFrontiers in microbiology · 2022Review
- Comparative Whole-Genome Analysis of Russian Foodborne Multidrug-ResistantMicroorganisms · 2021Article
- Early Response of Antimicrobial Resistance and Virulence Genes Expression in Classical, Hypervirulent, and Hybrid hvKp-MDRAntibiotics (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
Abstract
Multidrug resistance (MDR) and hypervirulence (hv) have been long considered distinct evolutionary traits for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.